Lindsay Fischer

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.

Amy Martinez, BSN, RN, OCN, explains how her team incorporated the Timed-Up-and-Go test into their workflows on a radiology unit.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.

Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.

With a new approval for elacestrant, patients with ER+/HER2–, ESR1-mutated metastatic breast cancer have an oral alternative to fulvestrant.

A modified dosing schedule may make treatment with ipilimumab plus nivolumab more tolerable for patients with advanced renal cell carcinoma.